{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Shen MZ"],"funding":["Foundation for Innovative Research Groups of the National Natural Science Foundation of China"],"pagination":["862526"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8981086"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12"],"pubmed_abstract":["<h4>Objective</h4>We aimed to establish a model that can predict refractory/recurrent cytomegalovirus (CMV) infection after haploidentical donor (HID) hematopoietic stem cell transplantation (HSCT).<h4>Methods</h4>Consecutive acute leukemia patients receiving HID HSCT were enrolled (n = 289). We randomly selected 60% of the entire population (n = 170) as the training cohort, and the remaining 40% comprised the validation cohort (n = 119). Patients were treated according to the protocol registered at https://clinicaltrials.gov (NCT03756675).<h4>Results</h4>The model was as follows: Y = 0.0322 × (age) - 0.0696 × (gender) + 0.5492 × (underlying disease) + 0.0963 × (the cumulative dose of prednisone during pre-engraftment phase) - 0.0771 × (CD34+ cell counts in graft) - 1.2926. The threshold o"],"journal":["Frontiers in cellular and infection microbiology"],"pubmed_title":["A Predicted Model for Refractory/Recurrent Cytomegalovirus Infection in Acute Leukemia Patients After Haploidentical Hematopoietic Stem Cell Transplantation."],"pmcid":["PMC8981086"],"funding_grant_id":["81621001"],"pubmed_authors":["Han W","Wang FR","Xu LP","Chen H","Wang JZ","Wang J","Shen MZ","Zhang XH","Huang XJ","Yan CH","Hong SD","Chen YH","Mo XD","Liu KY","Wang Y"],"additional_accession":[]},"is_claimable":false,"name":"A Predicted Model for Refractory/Recurrent Cytomegalovirus Infection in Acute Leukemia Patients After Haploidentical Hematopoietic Stem Cell Transplantation.","description":"<h4>Objective</h4>We aimed to establish a model that can predict refractory/recurrent cytomegalovirus (CMV) infection after haploidentical donor (HID) hematopoietic stem cell transplantation (HSCT).<h4>Methods</h4>Consecutive acute leukemia patients receiving HID HSCT were enrolled (n = 289). We randomly selected 60% of the entire population (n = 170) as the training cohort, and the remaining 40% comprised the validation cohort (n = 119). Patients were treated according to the protocol registered at https://clinicaltrials.gov (NCT03756675).<h4>Results</h4>The model was as follows: Y = 0.0322 × (age) - 0.0696 × (gender) + 0.5492 × (underlying disease) + 0.0963 × (the cumulative dose of prednisone during pre-engraftment phase) - 0.0771 × (CD34+ cell counts in graft) - 1.2926. The threshold o","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-05-31T06:01:39.861Z","creation":"2025-02-19T01:55:19.95Z"},"accession":"S-EPMC8981086","cross_references":{"pubmed":["35392613"],"doi":["10.3389/fcimb.2022.862526"]}}